Curated News
By: NewsRamp Editorial Staff
March 23, 2026
Soligenix Unveils Promising HyBryte™ Data for CTCL Treatment Ahead of Key Conference
TLDR
- Soligenix's HyBryte shows superior results versus Valchlor in CTCL treatment, offering a potential market advantage for investors and patients seeking effective therapies.
- HyBryte is a photodynamic therapy using synthetic hypericin and visible light, with positive long-term trial data supporting its development for regulatory approval in CTCL.
- This new treatment option for cutaneous T-cell lymphoma could improve patient outcomes and quality of life for those with rare diseases.
- Soligenix's novel photodynamic therapy harnesses visible light to treat CTCL, with data being presented at a major dermatology workshop in 2026.
Impact - Why it Matters
This news matters because it highlights a potential breakthrough in treating cutaneous T-cell lymphoma, a rare and often debilitating cancer with limited therapeutic options. The positive trial data for HyBryte™ could lead to regulatory approvals, offering patients a new, safer photodynamic therapy that uses visible light, reducing side effects compared to existing treatments. For investors, it signals Soligenix's progress in its pipeline, potentially boosting stock value and attracting partnerships. In the broader context, advancements in rare disease therapies address critical unmet medical needs, improving patient outcomes and quality of life. Additionally, Soligenix's work in public health vaccines, like CiVax™ for COVID-19, underscores its role in global health security, making this development relevant for both medical and investment communities.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, has announced that new supportive trial data for its novel therapy HyBryte™ will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026. The presentations will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor®, positioning HyBryte™ as a promising therapeutic option for cutaneous T-cell lymphoma (CTCL). This development is part of Soligenix's Specialized BioTherapeutics business segment, which focuses on addressing unmet medical needs in rare diseases. The company's pipeline also includes expansion into psoriasis with SGX302, and other programs like dusquetide for inflammatory diseases.
Beyond oncology, Soligenix's Public Health Solutions business segment is advancing vaccine candidates, including RiVax® for ricin toxin and CiVax™ for COVID-19, supported by government funding from agencies like NIAID and BARDA. The news was disseminated via BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN, which provides enhanced press release distribution and social media outreach to amplify such announcements. For more details, readers can visit the full press release through the provided link.
This update underscores Soligenix's commitment to innovation in both rare disease therapeutics and public health, leveraging partnerships and strategic communications to reach investors and the broader public. The upcoming presentation at a key dermatology event could pave the way for regulatory approvals and commercialization of HyBryte™, offering hope for patients with CTCL. As the company progresses, stakeholders can stay informed through resources like the company's newsroom, accessible via the provided link to BioMedWire.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Unveils Promising HyBryte™ Data for CTCL Treatment Ahead of Key Conference
